Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Friedman

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
G3 (Bethesda, Md.)|December 10, 2024
The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination eventChristopher A Simeone, Michelle T McNulty, Yask Gupta, et al.
Cancer Immunology Research|June 2, 2021
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune ResponsesDavid J Friedman, Sydney B Crotts, Michael J Shapiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2022
Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout MiceDavid J Friedman, Monika Kizerwetter, Paul Belmonte, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2019
Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicityJustin Chun, Jia-Yue Zhang, Maris S Wilkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel diseaseDavid J Friedman, Beat M Künzli, Yousif I A-Rahim, et al.
Kidney International Reports|July 19, 2019
APOL1-Associated Kidney Disease in BrazilCristian Riella, Tobias A Siemens, Minxian Wang, et al.
Kidney International|August 24, 2024
Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2Esilida Sula Karreci, Sonako Jacas, Olivia Donovan, et al.
Plos One|May 2, 2015
Copy Number Variation at the APOL1 LocusRupam Ruchi, Giulio Genovese, Jessica Lee, et al.
Journal of the American Society of Nephrology : JASN|August 7, 2010
The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African AmericansBarry I Freedman, Jeffrey B Kopp, Carl D Langefeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
G3 (Bethesda, Md.)|December 10, 2024
The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination eventChristopher A Simeone, Michelle T McNulty, Yask Gupta, et al.
Cancer Immunology Research|June 2, 2021
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune ResponsesDavid J Friedman, Sydney B Crotts, Michael J Shapiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2022
Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout MiceDavid J Friedman, Monika Kizerwetter, Paul Belmonte, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2019
Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicityJustin Chun, Jia-Yue Zhang, Maris S Wilkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel diseaseDavid J Friedman, Beat M Künzli, Yousif I A-Rahim, et al.
Kidney International Reports|July 19, 2019
APOL1-Associated Kidney Disease in BrazilCristian Riella, Tobias A Siemens, Minxian Wang, et al.
Kidney International|August 24, 2024
Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2Esilida Sula Karreci, Sonako Jacas, Olivia Donovan, et al.
Plos One|May 2, 2015
Copy Number Variation at the APOL1 LocusRupam Ruchi, Giulio Genovese, Jessica Lee, et al.
Journal of the American Society of Nephrology : JASN|August 7, 2010
The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African AmericansBarry I Freedman, Jeffrey B Kopp, Carl D Langefeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
Pageof 9